Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …

Background Obesity is a major risk factor for many leading causes of illness and death
worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon …

Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

Importance The effect of continued treatment with tirzepatide on maintaining initial weight
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical …

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …

Importance The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …

With an increasing prevalence of obesity, there is a need for new therapies to improve body
weight management and metabolic health. Multireceptor agonists in development may …

Objective To compare the benefits and harms of drug treatments for adults with type 2
diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) …

Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …